Concurrent advanced HIV disease and viral load suppression in a high-burden setting: Findings from the 2015-6 ZIMPHIA survey.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
11
2019
accepted:
24
02
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
20
8
2020
Statut:
epublish
Résumé
As Zimbabwe approaches epidemic control of HIV, programs now prioritize viral load over CD4 monitoring, making it difficult to identify persons living with HIV (PLHIV) suffering from advanced disease (AD). We present an analysis of cross-sectional ZIMPHIA data, highlighting PLHIV with AD and concurrent viral load suppression (VLS). ZIMPHIA collected blood specimens for HIV testing from 22,501 consenting adults (ages 15 years and older); 3,466 PLHIV had CD4 and VL results. Household HIV testing used the national serial algorithm, and those testing positive then received point-of-care CD4 enumeration with subsequent VL testing. We used logistic regression analysis to explore factors associated with concurrent AD and VLS (<1000 copies/mL). All analyses were weighted to account for complex survey design. Of the 3,466 PLHIV in the survey with CD4 and VL results, 17% were found to have AD (CD4<200cells/mm3). Of all AD patients, 30% had VLS. Concurrent AD and VLS was associated with male sex (aOR 2.45 95%CI 1.61-3.72), older age (35-49 years [aOR 2.46 95%CI 1.03-5.91] and 50+ years [aOR 4.82 95%CI 2.02-11.46] vs 15-24 years), and ART duration (<6 months [aOR 0.46 95%CI 0.29-0.76] and 6-24 months [aOR 2.07 95%CI 1.35-3.17] vs more than 2 years). The relationship between sex and AD is driven by age with significant associations among men aged 25-34, (aOR 3.37 95%CI 1.35-8.41), 35-49 (aOR 5.13 95%CI 2.16-12.18), and 50+ (aOR 12.56 95%CI 4.82-32.72) versus men aged 15-24. The percentage of PLHIV with AD and VLS illustrates the conundrum of decreased support for CD4 monitoring, as these patients may not receive appropriate clinical services for advanced HIV disease. In high-prevalence settings such as Zimbabwe, CD4 monitoring support warrants further consideration to differentiate care appropriately for the most vulnerable PLHIV. Males may need to be prioritized, given their over-representation in this sub-population.
Sections du résumé
BACKGROUND
As Zimbabwe approaches epidemic control of HIV, programs now prioritize viral load over CD4 monitoring, making it difficult to identify persons living with HIV (PLHIV) suffering from advanced disease (AD). We present an analysis of cross-sectional ZIMPHIA data, highlighting PLHIV with AD and concurrent viral load suppression (VLS).
METHODS
ZIMPHIA collected blood specimens for HIV testing from 22,501 consenting adults (ages 15 years and older); 3,466 PLHIV had CD4 and VL results. Household HIV testing used the national serial algorithm, and those testing positive then received point-of-care CD4 enumeration with subsequent VL testing. We used logistic regression analysis to explore factors associated with concurrent AD and VLS (<1000 copies/mL). All analyses were weighted to account for complex survey design.
RESULTS
Of the 3,466 PLHIV in the survey with CD4 and VL results, 17% were found to have AD (CD4<200cells/mm3). Of all AD patients, 30% had VLS. Concurrent AD and VLS was associated with male sex (aOR 2.45 95%CI 1.61-3.72), older age (35-49 years [aOR 2.46 95%CI 1.03-5.91] and 50+ years [aOR 4.82 95%CI 2.02-11.46] vs 15-24 years), and ART duration (<6 months [aOR 0.46 95%CI 0.29-0.76] and 6-24 months [aOR 2.07 95%CI 1.35-3.17] vs more than 2 years). The relationship between sex and AD is driven by age with significant associations among men aged 25-34, (aOR 3.37 95%CI 1.35-8.41), 35-49 (aOR 5.13 95%CI 2.16-12.18), and 50+ (aOR 12.56 95%CI 4.82-32.72) versus men aged 15-24.
CONCLUSIONS
The percentage of PLHIV with AD and VLS illustrates the conundrum of decreased support for CD4 monitoring, as these patients may not receive appropriate clinical services for advanced HIV disease. In high-prevalence settings such as Zimbabwe, CD4 monitoring support warrants further consideration to differentiate care appropriately for the most vulnerable PLHIV. Males may need to be prioritized, given their over-representation in this sub-population.
Identifiants
pubmed: 32584821
doi: 10.1371/journal.pone.0230205
pii: PONE-D-19-31914
pmc: PMC7316262
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230205Subventions
Organisme : PEPFAR
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001226
Pays : United States
Déclaration de conflit d'intérêts
The following authors were employed by CDC at the time of manuscript development: Balachandra, Rogers, Ruangtragool, Oboho, Paulin, Parekh, Birhanu, and Hakim. The following authors were employed by ICAP/Columbia University at the time of manuscript development: Radin and Musuka. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
AIDS Patient Care STDS. 2014 Nov;28(11):575-8
pubmed: 25290988
SAHARA J. 2016 Dec;13(1):178-187
pubmed: 27762160
BMC Public Health. 2016 May 03;16:369
pubmed: 27142869
J Int AIDS Soc. 2014 Mar 03;17:18651
pubmed: 24594114
HIV AIDS (Auckl). 2013 Dec 06;5:309-19
pubmed: 24348073
PLoS One. 2013 Dec 09;8(12):e81037
pubmed: 24363808
MMWR Morb Mortal Wkly Rep. 2017 Jun 02;66(21):558-563
pubmed: 28570507
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S106-SS110
pubmed: 29514232
Open Forum Infect Dis. 2017 Jul 23;4(3):ofx156
pubmed: 28959700
PLoS One. 2016 Aug 10;11(8):e0160170
pubmed: 27509018
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146
pubmed: 29514235
AIDS. 2018 May 15;32(8):1043-1051
pubmed: 29547445
Pan Afr Med J. 2017 Jan 12;26:14
pubmed: 28450993
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S126-S131
pubmed: 29514239
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
AIDS. 2015 Jan 2;29(1):67-76
pubmed: 25562492
South Afr J HIV Med. 2017 Nov 30;18(1):717
pubmed: 29568637
BMC Infect Dis. 2014 Jun 17;14:331
pubmed: 24938526
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139
pubmed: 29514234
Curr Opin HIV AIDS. 2017 Mar;12(2):123-128
pubmed: 28059957
MMWR Morb Mortal Wkly Rep. 2018 May 18;67(19):552-555
pubmed: 29771871
S Afr Med J. 2017 Nov 27;107(12):1058-1064
pubmed: 29262956